All market readings.
Search a reading, filter by market and browse pages of nine analyses.
2026
Digital therapy: reimbursement does not create adoption
How compulsory-insurance coverage from 1 July 2026 turns a therapeutic app into a practical prescriber pathway.
Market reading →
2026
TARDOC 2026: the tariff change reaches every care pathway
How TARDOC and outpatient flat rates turn service lists, coding and controls into a defined diagnostic for practices and centres.
Market reading →
2026
KVG quality: organise the evidence before the form arrives
Article 58a KVG, the outpatient quality agreement and practice evidence: understand the timetable and build useful B2B support.
Market reading →
2026
Opening a medical practice: choosing the right canton takes evidence
How the coverage rates revised in 2025 turn the choice of practice location into a defined commercial diagnostic.
Market reading →
2026
Medtech surveillance: an annual report is only as sound as its signals
How Swissmedic's 2026 targeted action turns PMS plans, data and safety reports into a defined review service.
Market reading →
2026
swissdamed: which diagnostic comes first?
How manufacturers and Swiss authorised representatives can prioritise IVDs, prepare swissdamed and turn the 2026 deadline into a commercial decision.
Market reading →
2026
MedDO and the MRA: a new medtech border
How MedDO, the Switzerland–EU MRA and swissdamed reshape medical-device market access and support needs in 2026.
Market reading →
2026
MDR: extra time will not rescue a portfolio without decisions
How MDR adoption and extended transitions turn a medtech portfolio into decisions about evidence, capacity and market access.
Market reading →
2026
GDPR: prepare a European launch
How a Swiss business can qualify EU targeting, map its campaign and prepare buyer evidence before a commercial launch.
Market reading →